Clinical Trial

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
DZD9008 in combination with AZD4205 for the treatment of patients with advanced NSCLC with EGFR mutations who have progressed after standard treatment. The purpose of this study is to assess the safety and efficacy of this combination therapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-02-28; most recent amendment 2025-12-24.
Trial Details
NCT Number NCT06295432
Lead Sponsor Dizal Pharmaceuticals
Conditions Non-small Cell Lung Cancer
Enrollment 90 participants
Start Date 2023-06-01
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-31